<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3911">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643678</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-05-140</org_study_id>
    <nct_id>NCT04643678</nct_id>
  </id_info>
  <brief_title>Anakinra in the Management of COVID-19 Infection</brief_title>
  <official_title>Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It&#xD;
      is rapidly spreading worldwide, posing a severe threat to global health. Many therapeutics&#xD;
      have been investigated for the treatment of this disease with inconclusive outcomes.&#xD;
&#xD;
      Anakinra - an interleukin (IL)-1 receptor antagonist - had showed survival benefits in&#xD;
      patients with macrophage activation syndrome (MAS) and sepsis and was investigated for the&#xD;
      use in COVID-19 infection with promising outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Defined as WHO Clinical Progression score of &lt;6 [patient alive, not requiring invasive, non-invasive, or high flow oxygen therapy, vasopressors, dialysis or Extracorporeal membrane oxygenation (ECMO)].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WHO Clinical Progression Score</measure>
    <time_frame>Day 7</time_frame>
    <description>Change in WHO Clinical Progression Score between day 1 and day 7 [WHO Clinical Progression score: 0 (Uninfected) - 10 (Dead)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ICU admission</measure>
    <time_frame>Day 28</time_frame>
    <description>Time to ICU admission up to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Day 28</time_frame>
    <description>Incidence of adverse events up to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Day 28</time_frame>
    <description>Length of hospital stay up to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>All-cause mortality rate at hospital discharge or at 28 days, whichever is first</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Covid19</condition>
  <condition>Pneumonia</condition>
  <condition>Cytokine Release Syndrome</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>Anakinra Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anakinra + Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care Alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care</description>
    <arm_group_label>Anakinra Group</arm_group_label>
    <other_name>Kineret®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Patients will receive the Standard of Care therapy as per the local treatment protocol</description>
    <arm_group_label>Standard of Care Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Hospitalized adult (age ≥ 18yrs)&#xD;
&#xD;
          -  Confirmed COVID-19 diagnosis&#xD;
&#xD;
          -  Presence of respiratory distress in addition to signs of cytokine release syndrome&#xD;
&#xD;
          -  Radiological evidence of pneumonia&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergic reactions to the study medication or any component of the product.&#xD;
&#xD;
          -  Active bacterial, viral, TB, fungal infectious diseases&#xD;
&#xD;
          -  Received immunosuppressant or immunomodulatory in the past 30 days&#xD;
&#xD;
          -  Neutrophil count &lt; 500 cells/microliter&#xD;
&#xD;
          -  Platelets &lt; 50,000/microliter&#xD;
&#xD;
          -  Pregnant or breastfeeding females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Eman Elmekaty, PharmD</last_name>
    <phone>40254259</phone>
    <email>Eelmekaty@hamad.qa</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Eman Elmekaty, PharmD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

